PTC Therapeutics (PTCT) News Today $48.82 -0.07 (-0.14%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$48.25 -0.57 (-1.17%) As of 05/30/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PTCT Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives $63.75 Average Target Price from BrokeragesMay 31 at 2:21 AM | americanbankingnews.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Recommendation of "Moderate Buy" by BrokeragesPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the fourteen brokerages that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, four have given a hold rating, eigMay 29 at 3:45 AM | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Stock Price Expected to Rise, Wells Fargo & Company Analyst SaysMay 29 at 1:31 AM | americanbankingnews.comWells Fargo & Company Forecasts Strong Price Appreciation for PTC Therapeutics (NASDAQ:PTCT) StockWells Fargo & Company raised their price objective on shares of PTC Therapeutics from $68.00 to $74.00 and gave the company an "overweight" rating in a research report on Tuesday.May 28 at 9:30 AM | marketbeat.comToronto Dominion Bank Invests $148.36 Million in PTC Therapeutics, Inc. (NASDAQ:PTCT)Toronto Dominion Bank purchased a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 3,286,729 shares of the biopharmaceutical company's stock, valuedMay 27, 2025 | marketbeat.comTwo Sigma Investments LP Has $7.83 Million Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)Two Sigma Investments LP decreased its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 45.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 173,352 shares of the biopharmaceutical company's stockMay 27, 2025 | marketbeat.comQuantinno Capital Management LP Makes New $436,000 Investment in PTC Therapeutics, Inc. (NASDAQ:PTCT)Quantinno Capital Management LP acquired a new position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The fund acquired 9,656 shares of the biopharmaceutical company's stock, valued at approximatelyMay 27, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCTMay 26, 2025 | prnewswire.comWoodline Partners LP Buys New Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)Woodline Partners LP purchased a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 155,883 shares of the biopharmaceutical company's stock, vaMay 26, 2025 | marketbeat.comState of Wyoming Makes New Investment in PTC Therapeutics, Inc. (NASDAQ:PTCT)State of Wyoming purchased a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 5,776 shares of the biopharmaceutical company's stock,May 26, 2025 | marketbeat.comBNP Paribas Financial Markets Has $465,000 Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)BNP Paribas Financial Markets reduced its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 85.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,292 shares of the biopharmaceutical cMay 26, 2025 | marketbeat.comProShare Advisors LLC Buys 6,164 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)ProShare Advisors LLC raised its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 32.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,102 shares of tMay 25, 2025 | marketbeat.comMillennium Management LLC Purchases 89,959 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)Millennium Management LLC boosted its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 41.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 309,423 shares of the biopharmaceutical cMay 25, 2025 | marketbeat.comBank of America Corp DE Sells 58,187 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)Bank of America Corp DE reduced its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 18.5% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 256,536 shares of the biopharmaceutical company's stock afterMay 25, 2025 | marketbeat.comVoloridge Investment Management LLC Sells 92,168 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)Voloridge Investment Management LLC decreased its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 14.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 568,364 shares of the biopharmaceMay 24, 2025 | marketbeat.comTwo Sigma Advisers LP Reduces Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)Two Sigma Advisers LP trimmed its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 16.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 360,442 shares of the biopharmaceutical comMay 24, 2025 | marketbeat.comThose who invested in PTC Therapeutics (NASDAQ:PTCT) three years ago are up 51%May 22, 2025 | finance.yahoo.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Stock Position Raised by Nuveen Asset Management LLCNuveen Asset Management LLC lifted its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 34.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,077,794 shares of the biopharmaceuticalMay 22, 2025 | marketbeat.comDeutsche Bank AG Boosts Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT)Deutsche Bank AG boosted its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 92.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 94,378 shares of the biopharmaceutical companyMay 22, 2025 | marketbeat.comRafferty Asset Management LLC Sells 23,231 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)Rafferty Asset Management LLC trimmed its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 22.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 78,032 shares of the biopharmaceutical compaMay 21, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCTMay 20, 2025 | prnewswire.comPTC Therapeutics, Inc. (NASDAQ:PTCT) VP Sells $40,635.66 in StockMay 20, 2025 | insidertrades.comLazard Asset Management LLC Acquires 34,069 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)Lazard Asset Management LLC lifted its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 294.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 45,647 shares of the biopharmaceutical compMay 20, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCTMay 18, 2025 | globenewswire.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Holdings Boosted by Point72 Asset Management L.P.Point72 Asset Management L.P. boosted its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 150.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,443,362 shares of the biopharmaceutical company'sMay 18, 2025 | marketbeat.comPoint72 Hong Kong Ltd Purchases 21,034 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)Point72 Hong Kong Ltd boosted its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 184.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 32,436 shares of the biopharmaceutical company's stMay 18, 2025 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Rating Lowered to Buy at StockNews.comStockNews.com downgraded shares of PTC Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday.May 18, 2025 | marketbeat.com14,998 Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT) Acquired by Graham Capital Management L.P.Graham Capital Management L.P. bought a new position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 14,998 shares of the biopharmaceutical company's stock,May 17, 2025 | marketbeat.comMPM Bioimpact LLC Has $19.63 Million Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)MPM Bioimpact LLC raised its stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 384.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 434,767 shares of the biopharmaceutical comMay 16, 2025 | marketbeat.comParkman Healthcare Partners LLC Has $8.01 Million Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)Parkman Healthcare Partners LLC reduced its stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 9.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 177,368 shares of the biopharmaceuticalMay 16, 2025 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Position Lifted by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLCOCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 49.2% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 46,894 shares of the biopharmaceuticalMay 15, 2025 | marketbeat.comJanus Henderson Group PLC Has $105.02 Million Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)Janus Henderson Group PLC boosted its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 24.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,325,915 shares of the biopharmaceutical company's stock after purchasiMay 15, 2025 | marketbeat.comDimensional Fund Advisors LP Takes $4.74 Million Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)Dimensional Fund Advisors LP bought a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 105,050 shares of the biopharmaceutical company's stockMay 15, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Sells 659,778 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)Jacobs Levy Equity Management Inc. trimmed its position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 44.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 826,519 shares of the biopharmaceutical company's stockMay 14, 2025 | marketbeat.comNorthern Trust Corp Grows Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)Northern Trust Corp lifted its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 7.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 727,976 shares of the biopharmaceuticalMay 13, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCTMay 12, 2025 | prnewswire.comBrevan Howard Capital Management LP Takes $551,000 Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)Brevan Howard Capital Management LP purchased a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 12,197 shares of the biopharmaceutical coMay 12, 2025 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Rating Increased to Buy at Bank of AmericaBank of America upgraded PTC Therapeutics from a "neutral" rating to a "buy" rating and set a $68.00 target price for the company in a report on Friday.May 11, 2025 | marketbeat.comLeerink Partnrs Has Bullish Forecast for PTCT Q1 EarningsPTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Investment analysts at Leerink Partnrs lifted their Q1 2025 earnings estimates for PTC Therapeutics in a report issued on Tuesday, May 6th. Leerink Partnrs analyst J. Schwartz now forecasts that the biopharmaceutical company will post earningsMay 11, 2025 | marketbeat.comWilliam Blair Lifts Earnings Estimates for PTC TherapeuticsPTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Equities researchers at William Blair increased their Q1 2025 earnings per share estimates for shares of PTC Therapeutics in a report released on Wednesday, May 7th. William Blair analyst S. Corwin now expects that the biopharmaceutical companyMay 11, 2025 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Purchased by Cubist Systematic Strategies LLCCubist Systematic Strategies LLC raised its stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 133.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 141,410 shares of the biopharmaceMay 11, 2025 | marketbeat.comPTC Therapeutics, Inc. (PTCT): Among Billionaire David E. Shaw’s Small-Cap Stock Picks with Huge Upside PotentialMay 10, 2025 | insidermonkey.comPTC Therapeutics, Inc. (PTCT): Among Billionaire David E. Shaw’s Small-Cap Stock Picks with Huge Upside PotentialMay 10, 2025 | finance.yahoo.comDriehaus Capital Management LLC Makes New $46.99 Million Investment in PTC Therapeutics, Inc. (NASDAQ:PTCT)Driehaus Capital Management LLC bought a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 1,041,059 shares of the biopharmaceutical coMay 10, 2025 | marketbeat.comAQR Capital Management LLC Sells 32,230 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)AQR Capital Management LLC cut its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 17.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 157,349 shares of the biMay 10, 2025 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Shares Gap Up Following Strong EarningsPTC Therapeutics (NASDAQ:PTCT) Shares Gap Up on Strong EarningsMay 9, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCTMay 9, 2025 | globenewswire.comCantor Fitzgerald Cuts PTC Therapeutics (NASDAQ:PTCT) Price Target to $112.00Cantor Fitzgerald cut their target price on shares of PTC Therapeutics from $113.00 to $112.00 and set an "overweight" rating for the company in a research report on Wednesday.May 9, 2025 | marketbeat.comJPMorgan Chase & Co. Lowers PTC Therapeutics (NASDAQ:PTCT) Price Target to $67.00JPMorgan Chase & Co. dropped their price objective on PTC Therapeutics from $75.00 to $67.00 and set an "overweight" rating on the stock in a research note on Wednesday.May 9, 2025 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Upgraded to Neutral at CitigroupCitigroup raised shares of PTC Therapeutics from a "sell" rating to a "neutral" rating and lowered their target price for the stock from $50.00 to $40.00 in a research note on Wednesday.May 9, 2025 | marketbeat.com Get PTC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter. Email Address PTCT Media Mentions By Week PTCT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PTCT News Sentiment▼1.290.87▲Average Medical News Sentiment PTCT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PTCT Articles This Week▼178▲PTCT Articles Average Week Get PTC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ITCI News GMAB News RDY News MRNA News ASND News VTRS News QGEN News ROIV News RVMD News BPMC News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PTCT) was last updated on 5/31/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredAs Bitcoin supply vanishes, this Trump-aligned token could explodeBitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PTC Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PTC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PTCT Stock Free PTCT Stock Alerts